{"id":"https://genegraph.clinicalgenome.org/r/1f0448e9-38c2-417e-8678-a66ab0bf5651v1.0","type":"EvidenceStrengthAssertion","dc:description":"PIGH was first reported in relation to autosomal recessive glycosylphosphatidylinositol biosynthesis defect 17 in 2018 (Pagnamenta et al., PMID:29573052 and Nguyen et al. PMID:29603516). Three variants (initiation codon, missense) that have been reported in 6 probands in 4 publications (PMIDs 29573052, 29603516, 33156547, 35445667) are included in this curation. Patients have a range of symptoms, including seizures, hypotonia, autism, intellectual disability, and motor deficits. The disease mechanism appears to be biallelic loss of function. Heterozygous carriers are reportedly unaffected. This gene-disease relationship is also supported by in vitro and in vivo assays showing a deficiency in glycosylphosphatidylinositol (GPI) biosynthesis (PMIDs 29603516, 9463366). In summary, there is limited evidence to support this gene-disease relationship. Although more evidence is needed to support a causal role, no convincing evidence has emerged that contradicts the gene-disease relationship. This classification was approved by the ClinGen Congenital Disorders of Glycosylation GCEP on October 2nd, 2025 (SOP Version 11).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/1f0448e9-38c2-417e-8678-a66ab0bf5651","GCISnapshot":"https://genegraph.clinicalgenome.org/r/ef2829dc-c0a5-43f7-a633-36e828cbd4ae","calculatedEvidenceStrength":"Limited","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/ef2829dc-c0a5-43f7-a633-36e828cbd4ae_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10135","date":"2025-10-27T17:56:48.046Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/ef2829dc-c0a5-43f7-a633-36e828cbd4ae_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10135","date":"2025-10-02T16:00:00.000Z","role":"Approver"}],"curationReasons":["NewCuration"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ef2829dc-c0a5-43f7-a633-36e828cbd4ae_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2a10c865-fb92-4736-8537-f684a649f005_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2ea4a54f-e272-4178-92da-1be5b8c1c17b","type":"EvidenceLine","dc:description":"Reduced due to consanguinity.","calculatedScore":4,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2ea4a54f-e272-4178-92da-1be5b8c1c17b_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Mutant cDNA was transfected into PIGH-deficient CHO cells. Restoration of GPI-AP was analyzed by FACS. Mutant PIGH could not efficiently restore surface expression of GPI-APs. Western blot showed a truncated version of PIGH, consistent with utilization of an alternate start codon in exon 2.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/2ea4a54f-e272-4178-92da-1be5b8c1c17b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29573052","allele":{"id":"https://genegraph.clinicalgenome.org/r/bade0bc4-27f0-40e3-84ce-1b6fd15ec487","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004569.5(PIGH):c.1A>T (p.Met1Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA7237630"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/2a10c865-fb92-4736-8537-f684a649f005","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29573052","rdfs:label":"Pagnamenta 2018 IV-1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":18,"allele":{"id":"https://genegraph.clinicalgenome.org/r/bade0bc4-27f0-40e3-84ce-1b6fd15ec487"},"detectionMethod":"WES on parents and proband, confirmed in affected sibling","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0000708","obo:HP_0001273","obo:HP_0001250","obo:HP_0004209"],"previousTesting":true,"previousTestingDescription":"Normal alkaline phosphatase, triglyceride levels. ","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/2ea4a54f-e272-4178-92da-1be5b8c1c17b_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/ef9f2535-b500-41fb-ab00-0dd2b77b023a_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3e11a2ed-e266-4ad4-a645-50c7b0dd3d8f","type":"EvidenceLine","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3e11a2ed-e266-4ad4-a645-50c7b0dd3d8f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35445667","allele":{"id":"https://genegraph.clinicalgenome.org/r/e5007a24-6845-4da8-8135-ee5a99f5a097","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004569.5(PIGH):c.487C>T (p.Arg163Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA7237506"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/ef9f2535-b500-41fb-ab00-0dd2b77b023a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35445667","rdfs:label":"do Rosario 2022 Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":2,"allele":{"id":"https://genegraph.clinicalgenome.org/r/e5007a24-6845-4da8-8135-ee5a99f5a097"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001250","obo:HP_0002421","obo:HP_0012448","obo:HP_0000750","obo:HP_0001999","obo:HP_0001252"],"previousTesting":false,"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/3e11a2ed-e266-4ad4-a645-50c7b0dd3d8f_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/769498ad-f1a6-4e79-a260-97291580257c_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/dc74414c-fb53-4cdf-bd27-619bf058c114","type":"EvidenceLine","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/dc74414c-fb53-4cdf-bd27-619bf058c114_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33156547","allele":{"id":"https://genegraph.clinicalgenome.org/r/62cf65bf-53aa-4747-86ab-db59f45c6c43","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004569.5(PIGH):c.307T>C (p.Ser103Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA7237577"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/769498ad-f1a6-4e79-a260-97291580257c","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33156547","rdfs:label":"Tremblay-Laganiere Proband 1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":4,"allele":{"id":"https://genegraph.clinicalgenome.org/r/62cf65bf-53aa-4747-86ab-db59f45c6c43"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0002186","obo:HP_0001260","obo:HP_0000729","obo:HP_0001263","obo:HP_0001252"],"previousTesting":true,"previousTestingDescription":"Granulocytes were tested for GPI-AP levels and compared to his unaffected het parents. FLAER, CD55, and CD59 were normal but CD16 levels were decreased by 60%.","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/dc74414c-fb53-4cdf-bd27-619bf058c114_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/dfb0fec2-fadb-47b0-8309-c578e6fa1765_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/29a7a976-c452-4764-ad48-d4f5df6e6061","type":"EvidenceLine","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/29a7a976-c452-4764-ad48-d4f5df6e6061_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33156547","allele":{"id":"https://genegraph.clinicalgenome.org/r/e5007a24-6845-4da8-8135-ee5a99f5a097"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/dfb0fec2-fadb-47b0-8309-c578e6fa1765","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33156547","rdfs:label":"Tremblay-Laganiere Proband 2","ageType":"AgeAtReport","ageUnit":"Years","ageValue":20,"allele":{"id":"https://genegraph.clinicalgenome.org/r/e5007a24-6845-4da8-8135-ee5a99f5a097"},"detectionMethod":"Unclear genotyping methods from the paper","phenotypes":["obo:HP_0011843","obo:HP_0011968","obo:HP_0001250","obo:HP_0001999","obo:HP_0000486","obo:HP_0012448","obo:HP_0002186","obo:HP_0001252","obo:HP_0000252","obo:HP_0001263"],"previousTesting":true,"previousTestingDescription":"Hearing exam, amino acids, urine organic acids, acylcarnitines, and ver long-chain fatty acid levels were normal","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/29a7a976-c452-4764-ad48-d4f5df6e6061_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/3539ef17-9a55-42f8-9f72-fabafc8b7f3f_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c8284115-9bf3-4864-b70e-8f289142c151","type":"EvidenceLine","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c8284115-9bf3-4864-b70e-8f289142c151_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33156547","allele":{"id":"https://genegraph.clinicalgenome.org/r/62cf65bf-53aa-4747-86ab-db59f45c6c43"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/3539ef17-9a55-42f8-9f72-fabafc8b7f3f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33156547","rdfs:label":"Tremblay-Laganiere Proband 3","ageType":"AgeAtReport","ageUnit":"Years","ageValue":4,"allele":{"id":"https://genegraph.clinicalgenome.org/r/62cf65bf-53aa-4747-86ab-db59f45c6c43"},"detectionMethod":"Genotyping methods unclear from the paper","phenotypes":["obo:HP_0001263","obo:HP_0001252","obo:HP_0001250"],"previousTesting":true,"previousTestingDescription":"Normal alkaline phosphatase, normal ferritin, elevated plasma iron","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/c8284115-9bf3-4864-b70e-8f289142c151_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/3f6cb83d-56fb-41a8-93c4-491792815989_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/250e2d38-613e-4e1b-b259-aa6a227418ba","type":"EvidenceLine","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/250e2d38-613e-4e1b-b259-aa6a227418ba_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29603516","allele":{"id":"https://genegraph.clinicalgenome.org/r/62cf65bf-53aa-4747-86ab-db59f45c6c43"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/3f6cb83d-56fb-41a8-93c4-491792815989","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29603516","rdfs:label":"Nguyen 2018 Proband","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":2,"allele":{"id":"https://genegraph.clinicalgenome.org/r/62cf65bf-53aa-4747-86ab-db59f45c6c43"},"detectionMethod":"Trio WES","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001252","obo:HP_0000717","obo:HP_0011343"],"previousTesting":true,"previousTestingDescription":"Normal alkaline phosphatase. A plasma acylcarnitine profile showed mildly increased levels of C8, C10:1, and C10, but with normal C8/C10 ratio. As shown in Figure 1, CD16 at the cell surface of granulocytes was decreased by up to 51% when compared with both parents, who are asymptomatic, and each carry a heterozygous mutation. ","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/250e2d38-613e-4e1b-b259-aa6a227418ba_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/ef2829dc-c0a5-43f7-a633-36e828cbd4ae_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/53bf12da-00c5-4be0-8380-2f2ae040110f_proband_segregation","type":"FamilyCosegregation","dc:description":"Genotyping methods were not clear. Parents not tested.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33156547","rdfs:label":"Tremblay-Laganiere Family 2","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/53bf12da-00c5-4be0-8380-2f2ae040110f","type":"Family","rdfs:label":"Tremblay-Laganiere Family 2","member":{"id":"https://genegraph.clinicalgenome.org/r/dfb0fec2-fadb-47b0-8309-c578e6fa1765"}},"meetsInclusionCriteria":false,"phenotypeNegativeAlleleNegative":0,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0001999","obo:HP_0001252","obo:HP_0012448","obo:HP_0000252","obo:HP_0001250","obo:HP_0001263","obo:HP_0002186","obo:HP_0000486","obo:HP_0011968","obo:HP_0011843"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/dfb0fec2-fadb-47b0-8309-c578e6fa1765"}},{"id":"https://genegraph.clinicalgenome.org/r/0e6ad6c7-da90-435f-9b40-92d722fafa56_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29573052","rdfs:label":"Pagnamenta 2018 Family","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/0e6ad6c7-da90-435f-9b40-92d722fafa56","type":"Family","rdfs:label":"Pagnamenta 2018 Family","member":{"id":"https://genegraph.clinicalgenome.org/r/2a10c865-fb92-4736-8537-f684a649f005"}},"meetsInclusionCriteria":true,"phenotypeNegativeAlleleNegative":0,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0001250","obo:HP_0001273","obo:HP_0000708"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/2a10c865-fb92-4736-8537-f684a649f005"},"sequencingMethod":{"id":"cg:AllGenesSequencing"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/ef2829dc-c0a5-43f7-a633-36e828cbd4ae_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ef2829dc-c0a5-43f7-a633-36e828cbd4ae_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e3c218a5-9a4b-4fd1-a994-0f9027d9f1a7","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f61f849e-e9e5-472a-b494-ea4799b89275","type":"FunctionalAlteration","dc:description":"As shown in Figure 1, CD16 at the cell surface of granulocytes was decreased by up to 51% when\ncompared with both parents, who are asymptomatic, and each carry a heterozygous mutation. 16 is used as a marker for GPI biosynthesis. CDVariants in the components of the GPI biosynthesis pathway had previously been identified in individuals with developmental delay and other features.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29603516","rdfs:label":"Nguyen 2019 Patient Cells"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/ef2829dc-c0a5-43f7-a633-36e828cbd4ae_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c5e44a05-843f-4ce7-95bc-15bf92f85be9","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/38efc69d-793f-40eb-ab82-0d24b06a3022","type":"Finding","dc:description":"The first step of GPI anchor biosynthesis, the transfer of N-acetylglucosamine (GlcNAc) from uridine 5-prime-diphospho-N-acetylglucosamide (UDP-GlcNAc) to PI to yield GlcNAc-PI, is catalyzed by a 7-subunit enzymatic complex that includes PIGA, PIGC (601730), PIGH (600154), PIGP (605938), PIGQ (605754), PIGY (610662), and DPM2 (603564). CD16 is often used as a biomarker for assessing GPI-anchor biogenesis. CD16 was found to be reduced in patient cells from Tremblay-Laganiere, 2021. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9463366","rdfs:label":"Biochemical function","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":1.5}],"evidenceStrength":"Limited","sequence":12127,"specifiedBy":"GeneValidityCriteria11","strengthScore":4.5,"subject":{"id":"https://genegraph.clinicalgenome.org/r/L4pAI-l92bo","type":"GeneValidityProposition","disease":"obo:MONDO_0060724","gene":"hgnc:8964","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_ef2829dc-c0a5-43f7-a633-36e828cbd4ae-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}